Tyrosine kinase inhibitorFDA-approvedSecond-line
Neratinib
How it works
Blocks the HER2 receptor on cancer cells, preventing growth signals and inhibiting cell division.
Cancer types
Breast Cancer— HER2-positive
Efficacy
Clinical trials have demonstrated that neratinib can improve progression-free survival in HER2-positive patients who have received prior therapy.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a Combination Therapy for ER-Positive, HER-2 Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Neratinib May Help Reduce Vascular Inflammation and Atherosclerosis | Breast Cancer | animal-study | Treatment with neratinib decreased the plaque burden, reduced the necrotic core size, and mitigated lesional macrophage infiltration. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.